Of the late-breaking clinical trials to be presented on Sunday, March 11, at the annual meeting of the American College of Cardiology in Orlando, the meeting’s vice chair, Andrew Kates, MD, highlighted two in a press briefing: ARTEMIS and MOMENTUM 3.
ARTEMIS
The investigators of this unique trial sought to determine whether reducing patients’ cost burden for their medication would improve adherence and, in turn, improve patient outcomes.
Specifically, ARTEMIS (Affordability and Real-World Antiplatelet Treatment Effectiveness After Myocardial Infarction Study) evaluated whether eliminating copayments for patients after acute MI could optimize antiplatelet therapy selection and long-term adherence, as well as patient outcomes and overall cost of care following acute MI.
Dr. Andrew Kates
Dr. Kates, professor of medicine, Washington University, St. Louis, said ARTEMIS would go far in answering the question, “If costs are lowered, are guidelines followed?”
Tracy Wang, MD, of Duke University, Durham, N.C., will present the results on Sunday in a joint Late-Breaking Clinical Trial session with JAMA, being held at 8 a.m.-9 a.m. in the Main Tent (Hall C).